Summary of important intrabodies in the preclinical phases of development
| Compound name | Protein target | Disease | Trial stage |
|---|---|---|---|
| β42-Specific scFv | Amyloid-β | Alzheimer’s disease | Pre-clinical |
| Anti-α-syn—PEST nanobodies | α-Syn | Parkinson’s disease | Pre-clinical |
| Anti-HTT | Huntington | HD | Pre-clinical |
| EGFR-specific scFvs | EGFR | Epidermoid carcinoma | Pre-clinical |
| Anti-folate receptor | Folate receptor | Ovarian cancer | Pre-clinical |
| LL3 (anti-β-catenin intrabodies) | β-catenin | Familial adenomatous polyposis | Pre-clinical |
α-Syn: α-synuclein; PEST: proteosome-targeting proline, aspartate or glutamate, serine, and threonine motif